Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies☆

https://doi.org/10.1016/S0002-9149(03)00626-XGet rights and content

Abstract

In clinical practice, we found no significant difference between atorvastatin therapy or other statin therapies in the clinical outcomes of patients with acute coronary syndromes receiving clopidogrel therapy. In patients receiving atorvastatin therapy, clopidogrel therapy was associated with a significant decrease in mortality and stroke during univariate analysis and a moderate trend of reduced mortality and stroke without statistical significance in the multivariate analysis.

References (9)

  • V.L. Serebruany et al.

    Statins do not affect platelet inhibition with clopidogrel during coronary stenting

    Atherosclerosis

    (2001)
  • W.C. Lau et al.

    Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation. A new drug-drug intervention

    Circulation

    (2003)
  • W.C. Lau et al.

    The antiplatelet activity of clopidogrel is inhibited by atorvastatin but not by pravastatin (abstr)

    Circulation

    (2000)
  • T.A. Clarke et al.

    The metabolism of clopidogrel is catalyzed by human cytochrome P 450 3A and is inhibited by atorvastatin

    Drug Metab Dispos

    (2003)
There are more references available in the full text version of this article.

Cited by (0)

☆

This study was supported the Landesversicherungsanstalt, Rheinland Pfalz, Germany; the Ministerium für Arbeit, Soziales und Gesundheit, Rheinland-Pfalz, Germany; MSD Sharp & Dohme, Haar, Germany; Bristol-Myers Squibb, München, Germany; Aventis Pharma, Bad Soden, Germany; AstraZeneca, Wedel, Germany; Pfizer, Karlsruhe, Germany; and Abbott, Ludwigshafen, Germany.

View full text
Copyright © 2003 Excerpta Medica Inc. All rights reserved.